Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE LANDSCAPE PART 09: MARKET SEGMENTATION BY CATEGORY • Segmentation by category • Comparison by category • Global immunosuppressants market • Global immuno boosters market • Market opportunity by category PART 10: MARKET SEGMENTATION BY INDICATION • Autoimmune diseases • Oncology • Organ transplantation • Others PART 11: CUSTOMER LANDSCAPE PART 12: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Immunology market in Americas • Immunology market in EMEA • Immunology market in APAC • Market opportunity PART 13: DECISION FRAMEWORK PART 14: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 15: MARKET TRENDS • Significant pipeline • Collaborations and partnerships for R&D • Advanced diagnostic technologies PART 16: VENDOR LANDSCAPE • Overview • Landscape disruption PART 17: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Amgen • F. Hoffmann-La Roche • Johnson & Johnson PART 18: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Parent market Exhibit 02: Global immunology market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global immunology market 2017-2022 ($ billions) Exhibit 09: Global immunology market: Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Key clinical trials Exhibit 20: Global immunology market by category 2017-2022 (%) Exhibit 21: Comparison by category Exhibit 22: Immunosuppressant drugs Exhibit 23: Global immunosuppressants market 2017-2022 ($ billions) Exhibit 24: Global immunosuppressants market: Year-over-year growth 2018-2022 (%) Exhibit 25: Classification of immuno boosters Exhibit 26: Global immuno boosters market 2017-2022 ($ billions) Exhibit 27: Global immuno boosters market: Year-over-year growth 2018-2022 (%) Exhibit 28: Market opportunity by category Exhibit 29: Brief history of immuno-oncology Exhibit 30: Stages of anti-tumor immune response Exhibit 31: Customer landscape Exhibit 32: Global immunology market by geography 2017-2022 (%) Exhibit 33: Regional comparison Exhibit 34: Immunology market in Americas 2017-2022 ($ billions) Exhibit 35: Immunology market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 36: Top three countries in Americas Exhibit 37: Immunology market in EMEA 2017-2022 ($ billions) Exhibit 38: Immunology market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 39: Top three countries in EMEA Exhibit 40: Immunology market in APAC 2017-2022 ($ billions) Exhibit 41: Immunology market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 42: Top three countries in APAC Exhibit 43: Market opportunity Exhibit 44: Rise in organ transplantation in US 2015-2016 Exhibit 45: Organ transplantation by donor type 2016 Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: AbbVie: Vendor overview Exhibit 52: AbbVie: Business segments Exhibit 53: AbbVie: Organizational developments Exhibit 54: AbbVie: Geographic focus Exhibit 55: AbbVie: Segment focus Exhibit 56: AbbVie: Key offerings Exhibit 57: Amgen: Vendor overview Exhibit 58: Amgen: Business segments Exhibit 59: Amgen: Organizational developments Exhibit 60: Amgen: Geographic focus Exhibit 61: Amgen: Segment focus Exhibit 62: Amgen: Key offerings Exhibit 63: F. Hoffmann-La Roche: Vendor overview Exhibit 64: F. Hoffmann-La Roche: Business segments Exhibit 65: F. Hoffman-La Roche: Organizational developments Exhibit 66: F. Hoffmann-La Roche: Geographic focus Exhibit 67: F. Hoffmann-La Roche: Segment focus Exhibit 68: F. Hoffmann-La Roche: Key offerings Exhibit 69: Johnson & Johnson: Vendor overview Exhibit 70: Johnson & Johnson: Business segments Exhibit 71: Johnson & Johnson: Organizational developments Exhibit 72: Johnson & Johnson: Geographic focus Exhibit 73: Johnson & Johnson: Segment focus Exhibit 74: Johnson & Johnson: Key offerings

AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Angimmune, Bionor Pharma, Boston Biomedical, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics, Forty Seven, HANSOH, Immatics Biatechnologies, lmmunovaccine, Karyopharm Therapeutics, MabVax Therapeutics, MedImmune, MOLOGEN, Neon Therapeutics, NewLink Genetics, Novartis, ONCOQUEST, and Oncotherapeutics.